Make Better Decisions - Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

Get the Book: Make Better Decisions

Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

PDF eBook: Just $10 Get Print Book on Amazon

Serving leading biopharmaceutical companies globally:

AstraZeneca
McKesson
Johnson and Johnson
Express Scripts
Colorcon
Moodys

Last Updated: October 20, 2019

DrugPatentWatch Database Preview

CLINICAL TRIALS PROFILE FOR SOMATULINE DEPOT

See Plans and Pricing

« Back to Dashboard

Clinical Trials for Somatuline Depot

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00149188 Somatuline Autogel: Acromegaly Self/Partner Injection Study Completed Ipsen Phase 4 2004-02-01 The purpose of this study is to allow patients with acromegaly, or their partners, to learn how to successfully inject Somatuline Autogel at home. Ability to perform unsupervised injections whilst maintaining adequate disease control will be assessed.
NCT00216398 Lanreotide Autogel in Patients With Acromegaly Previously Treated With Octreotide LAR Completed Ipsen Phase 4 2004-06-01 The purpose of this study is to assess the efficacy, safety and patient acceptability of Somatuline Autogel in patients with acromegaly previously treated with octreotide LAR.
NCT00288522 Lanreotide (Somatuline Autogel) in Thyroid-associated Ophthalmopathy Treatment Terminated Ipsen Phase 2 2006-01-01 The main purpose of this study is to evaluate the efficacy and safety of 3 doses of Somatuline Autogel 60mg to control the muscle infiltration and edema, eyelid retraction and extraocular muscular contraction in patients with active thyroid-associated ophthalmopathy of moderate intensity.
NCT00444873 Effect of 120mg Somatuline Autogel at Different Dose Intervals (28, 42 or 56 Days) in Patients With Acromegaly Completed Ipsen Phase 3 2005-01-01 A multicentre, prospective, open label study of acromegalic patients evaluating the efficacy and safety of different dose-intervals of Lanreotide Autogel 120mg according to international standards and compared to previous treatment with Octreotide LAR 10, 20 or 30 mg.
NCT00447499 Assessment of the Ability of Subjects With Acromegaly or Their Partners to Administer Somatuline Autogel Completed Ipsen Phase 3 2007-04-01 The purpose of this study is to determine whether subjects with acromegaly (or their partners) are able to self administer Somatuline Autogel at home.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for Somatuline Depot

Condition Name

Condition Name for Somatuline Depot
Intervention Trials
Acromegaly 9
Neuroendocrine Tumors 2
Neuroendocrine Tumours 2
Polycystic Liver Disease 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Condition MeSH

Condition MeSH for Somatuline Depot
Intervention Trials
Acromegaly 9
Carcinoid Tumor 7
Neuroendocrine Tumors 6
Syndrome 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Locations for Somatuline Depot

Trials by Country

Trials by Country for Somatuline Depot
Location Trials
United States 38
United Kingdom 5
Australia 4
Canada 4
Belgium 3
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Trials by US State

Trials by US State for Somatuline Depot
Location Trials
California 5
New York 3
Oregon 3
Mississippi 2
Michigan 2
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Progress for Somatuline Depot

Clinical Trial Phase

Clinical Trial Phase for Somatuline Depot
Clinical Trial Phase Trials
Phase 4 5
Phase 3 7
Phase 2 8
[disabled in preview] 4
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Status

Clinical Trial Status for Somatuline Depot
Clinical Trial Phase Trials
Completed 9
Recruiting 4
Not yet recruiting 3
[disabled in preview] 5
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Sponsors for Somatuline Depot

Sponsor Name

Sponsor Name for Somatuline Depot
Sponsor Trials
Ipsen 18
Radboud University 2
Universitair Ziekenhuis Brussel 1
[disabled in preview] 2
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Sponsor Type

Sponsor Type for Somatuline Depot
Sponsor Trials
Industry 18
Other 15
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

McKinsey
Express Scripts
Moodys
Johnson and Johnson
Boehringer Ingelheim
Merck

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.